Bli medlem
Bli medlem

Du är här


Elekta: Turkey's Medicana Health Group invests EUR 10 million in Elekta cancer treatment equipment

ANKARA, Turkey, May 11, 2016 - Elekta (EKTA-B.ST) announced today that
Medicana Health Group, one of Turkey's largest private health care
networks, invests more than EUR 10 million to purchase sophisticated
equipment and software to treat cancer.

The deal includes Elekta's Versa HD™ and Synergy Platform linear
accelerators as well as MOSAIQ® oncology information systems and
Monaco® treatment planning systems.

Salih Bilgin, Elekta's General Manager for Business Unit Turkey, says:
"Medicana is a growing hospital network, with increased focus on
cancer care. We are very happy to be able to support them in their
ambition to offer the highest quality health care services in Turkey.
Their choice of Elekta and our sophisticated Versa HD linear
accelerators together with Monaco treatment planning systems, will
provide their clinicians with unprecedented accuracy and speed."

Hüseyin Bozkurt, Medicana's Chairman, says the company desires to grow
with an increasing focus on cancer treatment. `'We plan to open five
new hospitals in the coming three years and to increase our presence
in the radiation therapy segment with top of the line, latest
technology linear accelerators, and fully integrated oncology
information systems. We will continue to provide the latest
developments in cancer treatment and the highest quality health
services in all our hospitals."

Elekta's sophisticated cancer treatment equipment will initially be
installed in hospitals in Ankara, Bursa, ?zmir and Istanbul. The
order was booked in the fourth quarter of Elekta's fiscal year
(2015-16) and the first delveries are expected in May, 2016.

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta

Tel: +31 653 561 242, e-mail:
Time zone: CET: Central European Time
Tobias Bülow, Director Financial Communication, Elekta AB
Tel: +46 722 215 017, e-mail:
Time zone: CET: Central European Time
The above information is such that Elekta AB (publ) shall make public
in accordance with the Securities Market Act and/or the Financial
Instruments Trading Act. The information was published at 07:30 CET
on May 11, 2016.

About Elekta
Elekta is a human care company pioneering significant innovations and
clinical solutions for treating cancer and brain disorders. The
company develops sophisticated, state-of-the-art tools and treatment
planning systems for radiation therapy, radiosurgery and
brachytherapy, as well as workflow enhancing software systems across
the spectrum of cancer care. Stretching the boundaries of science and
technology, providing intelligent and resource-efficient solutions
that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over
6,000 hospitals worldwide. Elekta employs around 3,800 employees
globally. The corporate headquarters is located in Stockholm, Sweden,
and the company is listed on NASDAQ Stockholm. Website:

About Medicana Healthcare Group's Cancer Treatment Units
Medicana Healthcare Group satisfies a significantly huge need of
cancer care in ?stanbul and Anatolia with its advanced cancer
treatment centers at hospitals in Ankara, ?stanbul, Konya, Samsun and

Some of our centers offer cutting-edge cancer treatment using
multislice Computed Tomography (MSCT), PET-CT, magnetic resonance,
ultrasonography, linear accelerator devices which can perform IMRT,
conventional radiology and nuclear medicine imaging methods or
radiation oncology and nuclear medicine units, which are present in
private sector hospital for the first time.

By closely following modern and sophisticated medical technologies,
Medicana Healthcare Group continuously updates its high-end device
substructure. The company offers patients the best diagnosis and
treatment opportunities available.


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.